Highlights
Primary Findings
Genetic evidence suggests that higher GLP-1 receptor (GLP-1R) expression is causally linked to a reduced risk of both type 2 diabetes mellitus (T2DM) and myocardial infarction (MI).
The Mediation Pathway
The cardioprotective effects against MI are largely driven by metabolic improvements, specifically glycated hemoglobin (HbA1c), body mass index (BMI), triglyceride levels, and blood pressure.
Absence of Direct Effect
Multivariate Mendelian randomization (MVMR) analysis indicates no significant direct effect of GLP-1R expression on MI risk independent of these metabolic mediators.
The Mechanistic Debate: Direct vs. Indirect Cardioprotection
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have fundamentally altered the management of type 2 diabetes and obesity. Beyond glycemic control, large-scale cardiovascular outcome trials (CVOTs), such as LEADER and SUSTAIN-6, have consistently demonstrated a reduction in major adverse cardiovascular events (MACE), including myocardial infarction. However, a persistent question in clinical cardiology and endocrinology has been whether these benefits stem from direct protective effects on the myocardium and vascular endothelium or are secondary to the systemic metabolic improvements induced by the drugs.
Preclinical studies have often suggested direct GLP-1R signaling in the heart may improve myocardial energy metabolism and endothelial function. Conversely, the profound weight loss, blood pressure reduction, and glucose-lowering effects observed in clinical practice suggest a systemic mediation. Understanding this distinction is critical for refining therapeutic strategies and identifying patients who will benefit most from GLP-1RA therapy.
Unveiling the Causal Pathway: A Mendelian Randomization Approach
To address the limitations of observational studies—such as confounding and reverse causation—Tong and colleagues employed a Mendelian randomization (MR) framework. This method uses genetic variants as instrumental variables to proxy the long-term biological effects of GLP-1R activation. By utilizing genetic data, the researchers could simulate a lifelong exposure to increased GLP-1R expression and evaluate its downstream effects on cardiovascular outcomes.
Study Design and Methodology
The researchers utilized a two-step MR analysis to quantify the mediating roles of various metabolic traits. The study integrated data from several high-profile genome-wide association studies (GWAS):
Genetic Proxies
Variants associated with GLP-1R expression were used as instrumental variables to proxy GLP-1RA treatment.
Mediators
Metabolic traits including HbA1c, BMI, lipid profiles (Triglycerides, HDL-cholesterol), and systolic blood pressure (SBP) were sourced from the Million Veteran Program.
Outcomes
Data for T2DM were obtained from the DIAGRAM consortium, while MI data were sourced from the UK Biobank and the CARDIoGRAMplusC4D consortium. All participants were of European ancestry to minimize population stratification bias.
Core Findings: The Mediating Power of Metabolic Traits
The study confirmed that higher genetically predicted GLP-1R expression correlates with a lower risk of T2DM (Odds Ratio [OR] 0.94; 95% CI 0.92–0.97) and a lower risk of MI (OR 0.97; 95% CI 0.95–1.00). The pivotal discovery, however, lay in the quantification of how much of the MI risk reduction was attributable to specific metabolic changes.
The Hierarchy of Mediation
The analysis revealed that metabolic improvements significantly mediated the relationship between GLP-1R expression and MI risk reduction:
1. HbA1c Improvement: Accounted for 36.67% (95% CI 3.89–69.44) of the effect.
2. BMI Reduction: Accounted for 28.86% (95% CI 2.62–55.10) of the effect.
3. Triglyceride Lowering: Accounted for 18.52% (95% CI 1.47–35.57) of the effect.
4. HDL-Cholesterol Increase: Accounted for 18.28% (95% CI 1.45–35.12) of the effect.
5. Systolic Blood Pressure Reduction: Accounted for 11.55% (95% CI 0.33–22.76) of the effect.
These findings suggest that nearly two-thirds of the cardioprotective benefit can be explained by the combined impact of glucose control and weight loss alone.
Decoupling Direct and Indirect Effects
One of the most significant aspects of this research was the use of multivariate Mendelian randomization (MVMR). This technique allows researchers to calculate the “direct effect” of an exposure after statistically adjusting for mediators. When the researchers adjusted for the combined metabolic traits, the association between GLP-1R expression and MI risk became statistically non-significant (beta = -0.003, P = 0.12).
This lack of a residual direct effect suggests that GLP-1RAs do not possess a unique, independent cardioprotective mechanism that bypasses metabolic health. Instead, their value in preventing myocardial infarction is inextricably linked to their ability to normalize the metabolic milieu.
Clinical Significance and Expert Interpretation
For clinicians, these results provide a clear physiological rationale for the use of GLP-1RAs. While the “direct vs. indirect” debate may seem academic, it has real-world implications for patient selection.
Prioritizing Metabolic Management
The data support the current clinical trend of using GLP-1RAs as primary tools for metabolic rehabilitation. The substantial mediation by BMI and HbA1c reinforces the idea that the greatest cardiovascular dividends are paid when these drugs successfully induce weight loss and glycemic stability.
Interpretation of Null Direct Effects
The absence of a direct effect in this MR study does not mean that GLP-1RAs do not act on the heart at all. Rather, it suggests that in the context of lifelong genetic exposure, the systemic metabolic benefits are the dominant forces in preventing MI. It is also important to note that MR reflects lifetime exposure, whereas clinical trials reflect short-term pharmacological intervention. However, the alignment between these genetic findings and trial data strengthens the evidence for metabolic mediation.
Expert Commentary
This study provides a high level of evidence clarifying that GLP-1RAs are, first and foremost, powerful metabolic modulators. While earlier hypotheses focused on specific GLP-1 receptors in the cardiac conduction system or coronary arteries, this mediation analysis redirects our focus to the systemic landscape. The findings emphasize that managing obesity and dysglycemia remains the most effective pathway to reducing myocardial infarction risk in patients with metabolic syndrome.
Conclusion
In conclusion, the cardioprotective benefits of GLP-1 receptor agonists against myocardial infarction are primarily mediated by improvements in glucose metabolism, body weight, and lipid profiles. The study finds no evidence of a significant direct effect independent of these pathways. These results underscore the importance of prioritizing comprehensive metabolic improvement as a primary goal in the prevention of cardiovascular disease among patients treated with GLP-1RAs.
References
Tong J, Li N, Hu F, Yue Y. Metabolic Improvement Mediates the Causal Relationship Between GLP-1 Receptor Agonists and Myocardial Infarction: A Mendelian Randomization and Mediation Analysis Study. Diabetes Care. 2026 Jan 1;49(1):171-178. doi: 10.2337/dc25-1822. PMID: 41259721.
